Genetic Risks for AMD in Australians of Northern and Southern European Origin

Principal Investigator
Luba Robman, MBBS, PhD
Centre for Eye Research Australia (Australia)
Melbourne, Australia
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2008 - March 31, 2010
Grant ID
M2008082
Goals
This study will investigate whether changes in diet can modify the genetic risk of AMD, which is predetermined by genes. To define genetic risk for AMD, the study will genotype AMD cases and controls from a large Australian cohort of participants of Anglo-Celtic and Mediterranean origin.
Summary
This study will investigate whether the risk of AMD, which is predetermined by genes, can be modified by changes in diet. The study will genotype AMD cases and controls from a large Australian cohort of Anglo-Celtic and Mediterranean origin participants to define the genetic risk for AMD. They will identify the AMD genes in elderly from this cohort (about 8,000 people), and correlate genetic status of the participants with their dietary history and condition of the retina. This might be the first step towards personalized medical care, based on knowledge of susceptibility to a disease using genetic and other risk factor information.
Grants
Related Grants
Macular Degeneration Research
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Neetu Kushwah, PhD
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Neetu Kushwah, PhD
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Krishna Singh, PhD
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shintaro Shirahama, MD, PhD